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Abstract: Pulmonary tumor thrombotic microangiopathy (PTTM) is a
rare clinical entity where tumor cell embolisms in pulmonary circulation
induce thrombotic microangiopathy (TMA), respiratory failure, and
subacute cor pulmonale.
We describe 3 cases of PTTM that presented as the initial mani-
festation of metastatic gastric adenocarcinoma with TMA and pulmon-
ary infiltrates.
All 3 cases had similar clinical and laboratory features, which
included moderate thrombocytopenia without renal failure, hemolysis
with extremely high serum lactate dehydrogenase levels, leukoerythro-
blastosis in peripheral blood smear, altered coagulation tests, lympha-
denopathies, and interstitial pulmonary infiltrates. All patients died
within 2 weeks of diagnosis. Two cases were initially misdiagnosed
as idiopathic thrombotic thrombocytopenic purpura and treated with
plasma exchange with no response. One patient had bone marrow
infiltration by malignant cells. Autopsies revealed PTTM associated
with gastric disseminated adenocarcinoma (signet-ring cell type in
2 patients and poorly differentiated type in 1).
PTTM should be considered in the differential diagnosis of patients
with fulminant microangiopathic hemolytic anemia, such as atypical
thrombotic thrombocytopenic purpura, mainly those with pulmonary
infiltrates, disseminated intravascular coagulation, or Trousseau syn-
drome.
(Medicine 2014;93: 359–363)
Abbreviations: aPTT = activated partial thromboplastin time,
ADAMTS-13 = a desintegrin and metalloprotease with a
thrombospondin type 1 motif, member 13, CT = computed
tomography, DAT = direct antiglobulin test, DIC = disseminated
intravascular coagulation, FDPs = fibrin degradation products,
ICU = intensive care unit, LDH = lactate dehydrogenase, LOS =
length of stay, MAHA = microangiopathic hemolytic anemia,
NHL = non-Hodgkin lymphoma, PT = prothrombin time, PTTM =
pulmonary tumor thrombotic microangiopathy, TMA = thromboticD, PhD, Arturo P hD,
D, PhD, and Josep M. Nicola´s, MD, PhD
INTRODUCTION
P ulmonary tumor thrombotic microangiopathy (PTTM) is arare clinical entity where tumor cell embolisms in pulmon-
ary circulation induce thrombotic microangiopathy (TMA),
respiratory failure, and subacute cor pulmonale. TMA is a
disorder characterized by thrombocytopenia, Coombs negative
microangiopathic hemolytic anemia (MAHA), and variable
degrees of organ dysfunction.23
Diagnosis of PTTM is challenging. It is often misdiag-
nosed as thrombotic thrombocytopenic purpura (TTP),23 and
the patient is started on plasma exchange therapy. However,
such treatment is ineffective and the disease usually progresses
quickly to a fatal outcome. Therefore, prompt etiologic diag-
nosis is very important because the only chance for the patient is
to achieve a response to tumor-specific chemotherapy. We
present hereby 3 patients with PTTM presenting with TMA
and lung involvement admitted to the same hospital. We note
that these patients presented features of TTP but with atypical
characteristics that can help to shape the differential diagnosis.
We also address other potential differential diagnoses.
PATIENTS AND METHODS
We describe 3 cases of PTTM that presented as the initial
manifestation of metastatic gastric adenocarcinoma with TMA
and pulmonary infiltrates. All 3 patients had similar clinical and
laboratory features and were admitted to the intensive care unit
(ICU) of the same hospital due to the severity and clinical
complications during the hospitalization. All patients died
within 2 weeks of diagnosis. As this is a retrospective and
descriptive study with no intervention, and figures do not show
identifiable patients, institutional review board approval and
informed consents were waived.
Literature Search
We also present a literature review based on relevant
articles for PTTM, TMA, MAHA, TTP, and Trousseau syn-
drome published in PubMed (National Library of Medicine,
Bethesda, MD) in the English language up to February 2014.
CASE REPORTS
The main clinical and laboratory features of the 3 cases are
summarized in Table 1.
Case 1
A 36-year-old Brazilian man without relevant past medical
history came to our hospital complaining of 1-week weakness
igns were normal and he was apyretic.
evealed pale skin, jaundice and petechiae
boratory tests showed signs of MAHA
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TABLE 1. Main Clinical and Laboratory Features of the 3 Cases
Case 1 Case 2 Case 3
Age (yr) 36 34 24
Sex Male Male Female
Presenting symptoms Weakness, dark urine Cough, back pain Back pain, nausea/vomiting
Laboratory test
Hemoglobin (g/L) 66 95 93
Platelet count (/L) 100 109 81 109 94 109
Creatinine (mg/dL) 0.8 0.7 0.8
LDH (U/L) 3057 2286 8450
PT (sec) 14 15 17
aPTT (sec) 26 30 45
Fibrinogen (g/L) 2.3 1.8 1.4
FDPs Increased Increased Increased
Peripheral blood smear Schistocytes Schistocytes Schistocytes
Leukoerythroblastosis 35% – –
Bone marrow Erythroid hyperplasia Erythroid hyperplasia Neoplastic cells
Lymphadenopathies Mediastinal Laterocervical Mediastinal Retroperitoneal
Celiac Retroperitoneal
Pulmonary infiltrates Yes Yes Yes
Plasma exchange Yes Yes No
Outcome Death Death Death
LOS (days) 2 12 2
Abbreviations: ADAMTS-13¼A disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13; aPTT¼ activated partial
tate
Gainza et al Medicine  Volume 93, Number 24, November 2014(hemoglobin 66 g/L, total bilirubin 4.1mg/dL, direct bilirubin
0.8mg/dL, reticulocyte count 190 109/L, lactate dehydrogen-
ase (LDH) 3057U/L, undetectable haptoglobin, and schisto-
cytes in the peripheral blood smear). White blood cell count and
creatinine were normal. Platelet count was 100 109/L,
prothrombin time (PT) was 14 sec, activated partial thrombo-
plastin time (aPTT) was 26 sec, fibrinogen was 2.3 g/L and
fibrinogen degradation products (FDPs) were increased. The
direct antiglobulin (Coombs) test (DAT) was negative. Bone
marrow aspiration detected erythroblastosis without abnormal-
ities in other lineages. Chest X-ray demonstrated bilateral
interstitial pulmonary infiltrates (Figure 1A) and the patient
was hypoxemic. He was admitted to the ICU with an initial
diagnosis of TTP and plasma exchange therapy was started
without improvement. Invasive mechanical ventilation was
needed due to progressive respiratory failure. Chest and
abdomen computed tomography (CT) demonstrated mediast-
inal and celiac lymphadenopathies. A result of ADAMTS-13
(a desintegrin and metalloprotease with a thrombospondin type
1motif, member 13) activity of 35% in the initial plasma sample
was received. Two days after admission the patient died due to
refractory hypoxemia. Autopsy was performed.
Case 2
A 34-year-old Peruvian man without relevant past
medical history presented to the emergency room referring
1 month of asthenia, cough, headache and lumbar pain. Physical
examination showed pale skin, jaundice, laterocervical lym-
phadenopathies and bilateral basal rales. In the laboratories he
thromboplastin time; FDPs¼fibrin degradation products; LDH¼ lac
PT¼ prothrombin time.presented elevated liver enzymes (aspartate aminotransferase
388U/l, alanine aminotransferase 75U/L, alkaline phosphatase
450U/L), signs of MAHA (hemoglobin 81 g/L, total bilirubin
360 | www.md-journal.com4.2mg/dL, direct bilirubin 1.3mg/dL, reticulocyte count
265 109/L, LDH 2286U/L, haptoglobin 0.071 g/L, and per-
ipheral blood smear with schistocytes) and platelet count of
95 109/L. Coagulation test showed PT 15 sec, aPTT 30 sec,
fibrinogen 1.8 g/L and increased FDPs. Creatinine was normal.
DAT was negative. Chest X-ray and CT scan demonstrated
bilateral interstitial infiltrates, infracentrimetric mediastinal and
retroperitoneal lymphadenopathies, hypodense hepatic lesions
and ascites. Bone marrow aspirate excluded infiltration by
malignant cells. Corticosteroids and plasma exchange were
administered with no improvement. A lymph node and a
percutaneous liver biopsy with a Tru-Cut needle were per-
formed showing metastatic gastric adenocarcinoma of signet-
ring cell type in the lymph node and sinusoidal infiltration by
carcinoma cells in the liver. The outcome was complicated with
hemoperitoneum after liver biopsy and the patient was trans-
ferred to the ICU. Administration of chemotherapy was ruled
out due to poor patient’s clinical condition. Twelve days after
admission the patient died of multiple organ dysfunction due to
several complications, such as pulmonary distress and Staphy-
lococcus aureus pneumonia. Autopsy was not done.
Case 3
A 24-year-old Bolivian woman without relevant past
medical history was referred to our hospital for further
study of 3-weeks back pain, nausea and vomiting. At admission
she appeared pale. Laboratory tests showed increased alkaline
phosphatase (855U/L), signs of MAHA (hemoglobin 93 g/dL,
total bilirubin 8.1mg/dL, direct bilirubin 2.3mg/dL, reticulo-
dehydrogenase; LOS¼ length of stay (from admission to death);cyte count 267 109/L, LDH 8450U/L, haptoglobin 0.04 g/L,
and schistocytes in peripheral blood smear), 94 109/L plate-
lets and signs of disseminated intravascular coagulopathy (DIC)
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FIGURE 1. A. Chest X-ray with interstitial bilateral infiltrates (Case 1). B. Schistocytes (arrows) and an erythroblast (arrowhead) in the
peripheral blood smear (Case 3). C. Neoplastic cells in bone marrow (arrows) (Case 3). D. Blood vessels with eccentric intimal fibrosis
(arrow), intravascular fibrin thrombi, and recanalization and intraluminal emboli of neoplastic cells (arrowhead) (hematoxylin and eosin,
riva
pha
Medicine  Volume 93, Number 24, November 2014 PTTM(PT 17 sec, aPTT 45 sec, fibrinogen 1.4 g/L and elevated FDPs).
Leukoerythroblastosis was also present in the peripheral blood
smear (Figure 1B). DATwas negative. Chest X-ray was normal,
but a CT scan demonstrated interstitial bilateral infiltrates,
hepatic lesions suggestive of multiple metastasis and retro-
peritoneal lymphadenopathies. A gastrointestinal endoscopy
was performed, observing an irregularly shaped ulcer with
headed up margins whose biopsy was compatible with gastric
adenocarcinoma. Bone marrow was infiltrated with neoplastic
epithelial cells (Figure 1C). After 48 hours of admission the
patient presented multiple organ dysfunction syndrome. As the
prognosis was fatal, no life support measures were initiated and
the patient died. An autopsy was performed.
Comment
In the 3 cases, anatomopathologic reports revealed gastric
adenocarcinoma (2 signet-ring cell type, 1 poorly differentiated
type [Case 3]), widespread microscopic metastatic deposits,
tumor cell embolism with local thrombosis in the pulmonary
arteries and arterioles, and fibrocellular intimal proliferation
(Figure 1D-E). Carcinomatous lymphangitis was also present in
the autopsies performed (Figure 1F). These findings confirmed
the diagnosis of PTTM secondary to microscopic tumor cell
embolism due to disseminated gastric adenocarcinoma.
DISCUSSION
PTTM is a rare clinicopathologic entity named by Von
Hervay in 1990,23 but first described by Brill and Robertson in
original magnification  100) (Case 3). E. Carcinoma emboli in pe
(Case 1). F. Autopsy specimen of the lung showing prominent lym
white lines (Case 3).1937 with the term ‘‘subacute cor pulmonale’’.1 Although
detailed pathogenesis remains to be clarified, it seems that
embolization of tumoral cells into the pulmonary vessels induce
# 2014 Lippincott Williams & Wilkinsendothelial damage and create a procoagulant environment with
local activation of coagulation and fibrocellular intimal pro-
liferation, leading to thrombosis and stenosis of vessels, with
resulting pulmonary hypertension and MAHA.14,23 Recent
reports suggest that vascular endothelial growth factor, tissue
factor, and activated alveolar macrophages in the lung via
expression of platelet-derived growth factor, may contribute
to the onset and/or progression of PTTM promoting fibrocel-
lular intimal proliferation.2,18,24 In addition, systemic activation
of coagulation involves the generation of intravascular fibrin
and the consumption of procoagulants, leading to DIC.
Although PTTM has been observed in 0.9% to 3.3% of
autopsy case studies with extrathoracic malignancies,14,23 only
a few cases are diagnosed antemortem.11,14 Different neoplasms
have been reported to be associated with PTTM,5,8,23 but
adenocarcinomas are the most frequently related. Gastric car-
cinoma is the most common (up to 26% of the cases described in
the literature) followed by breast (21%), prostate (13%), and
lung (10%) carcinoma. Although less frequent, PTTM has also
been observed in hematologic malignancies such as Hodgkin
lymphoma, aggressive non-Hodgkin lymphoma (NHL) and
myeloma.12 Furthermore, a high incidence of PTTM, up to
16.7%, has been described in the context of gastric carcinomas
(3.3% in malignant tumors in general).10 It is not well known
why gastric carcinoma is more frequently associated with
PTTM than other neoplasms. Interestingly, our 3 patients came
from Latin American countries and were younger than most of
the patients at gastric cancer diagnosis. Although the higher
incidence of gastric cancer is described in Asian countries, such
scular lymphatic vessels (arrows) (hematoxylin and eosin,  400)
tic vessels (carcinomatous lymphangitis) in pleural surface as fineas Japan and Korea, a high incidence has also been seen in
Central and South-America, as two-thirds of this malignancy is
produced in developing countries. Median age of patients
www.md-journal.com | 361
diagnosed with gastric cancer is around 50–70 years. However,
several authors have described that patients with gastric cancer
and cancer-related MAHA12 or PTTM3 are younger, regardless
of their country of origin. There have also been described cases
of PTTM associated with gastric cancer in children and ado-
lescent patients, although the prevalence of gastric cancer in
young generations is much lower.9
Patients with PTTM can present with different symptoms
(weakness, weight loss, pain, fever, and respiratory symp-
toms)6,8,14 and can mimic different syndromes such as pulmon-
ary hypertension, right heart failure,6,19 or organ dysfunction. In
some cases, including the patients reported herein, MAHA and
TMA are the predominant features of the clinical scenario, and
differential diagnosis with TTP is then mandatory. Current
diagnostic criteria of TTP include thrombocytopenia and
MAHA without another apparent etiology.7 However, these
clinical features are nonspecific and can be observed in other
clinical conditions, including PTTM, inducing an inappropriate
indication of plasma exchange therapy. It has been described
that up to 3% of patients diagnosed with TTP (and almost 7% of
the ‘‘idiopathic’’ cases) are really misdiagnosed MAHA sec-
ondary to a disseminated malignancy, whose main pathologic
mechanism is microthrombi formation by tumor cells.5 When
these microthrombi affect predominantly (but not only) pul-
monary vessels and produce respiratory signs and symptoms,
we call this entity PTTM. Thereby, although occult malignancy
causing MAHA may be uncommon (George8 et al described
65 cases of systemic malignancies associated with MAHA and
TMA in 30 years), it is important to consider it in the evaluation
of patients with TTP.
The cases in the current series reflect that PTTM and TMA
due to disseminated malignancy present some atypical clinical
and laboratory features that may help in the differential diag-
nosis.5,15 One of the main differences is the presence of
pulmonary involvement. Typically TTP has been reported to
spare the lungs. However, one should not consider that all TTP
cases with lung involvement are due to PTTM. Actually,
pulmonary affectation in TTP is more common than generally
appreciated: lung diseases can be the cause of a secondary TTP
(pneumonia, chemotherapy-induced lung toxicity); and the lung
can be involved in idiopathic TTP due to microthrombotic
occlusion of pulmonary vessels or intraparenchymal hemor-
rhage associated with thrombopenia.16 There exist other fea-
tures that are different in PTTM compared with TTP: a longer
duration of symptoms, moderate thrombocytopenia, higher
serum LDH levels, and abnormal coagulation tests. Regarding
the levels of ADAMTS-13, it has been described that PTTM
cases present a slight decrease instead of the severe deficient
activity (<5%) typically seen in idiopathic TTP.4,22 Leukoer-
ythroblastosis in peripheral blood smear and increase of alkaline
phosphatase could be indicative of bone marrow infiltration.
The detection of lymphadenopathies in the CT images is also a
common finding in PTTM. Finally, failure to response to
plasma exchange is another characteristic of these patients.5,8
Differential diagnosis with PTTM should be considered
not only in atypical TTP, but also in other conditions that may
present with fulminant MAHA and could mimic a similar
scenario, such as DIC or Trousseau syndrome. About one-third
of patients with cancer-related MAHA show laboratory signs
indicative of DIC, although malignancies can cause TMA
without coagulation abnormalities.12 Trousseau syndrome con-
Gainza et alsists of migratory thrombotic events that precede the diagnosis
of an occult visceral malignancy or appear concomitantly with
the tumor. It is consequence of multiple pathophysiologic
362 | www.md-journal.commechanisms that contribute to the hypercoagulability associated
with cancer, often occurring with mucin-positive carcinomas
although it may be associated with other different types of
cancer.20 It has been considered by some authors as a chronic or
compensated DIC in the set of malignancy, where there is a
slower rate of consumption of coagulation factors and platelets
because liver and bone marrow are largely able to replenish
them, so thrombosis manifestations are frequent rather than
bleeding events. The typical clinical picture is venous and
arterial microthrombi with secondary MAHA and that may
also be associated with alteration of coagulation tests. However,
in recent times, Trousseau syndrome is also used to describe any
thrombotic complication associated with cancer, and usually
affects large or medium vessels resulting in migratory throm-
bophlebitis, nonbacterial thrombotic endocarditis, arterial
emboli or deep vein thrombosis associated or not with
DIC,17 differently from the clinical course of PTTM, where
the principal location of the microvascular metastases is the
lung. There are also physiopathologic differences, as Trousseau
syndrome represents a spectrum of disorders, ranging with
thrombosis induced primarily by the production of tissue factor
by tumor cells, and platelet-rich microthrombotic process trig-
gered by carcinoma mucins and other mechanisms that leads to
thrombin generation and fibrin deposition, whereas the main
problem in PTTM are the cancer cells embolism, mainly in the
pulmonary microcirculation.20
Although pulmonary hypertension and cor pulmonale are
classical signs documented in several case reports, they were
not present in our patients. Actually, right ventricle enlargement
or hypertrophy appears in less than 50% of patients with
PTTM.6,21 Moreover, in the series of Von Herbay et al,23
11/21 patients with PTTM died due to causes different that
right cardiac failure. Essentially, patients with MAHA due to
metastatic cancer have TMA not only in the lung, but also in
other organs.8,13 Therefore, in our opinion, the term PTTM
should be considered as part of a more generalized picture
(‘‘tumor thrombotic microangiopathy’’) with TMA due to
micrometastasis in the vessels of diverse organs leading to
different possible clinical presentations.
Although most of the cases are diagnosed in autopsies, if
systematic malignancy is suspected, bone marrow biopsy, as
well as biopsies of any suspected involved organs, would be
appropriate.5
There are several reasons to make a prompt diagnosis of
the systemic malignancy underlying PTTM. First, it provides an
opportunity for treatment with appropriate chemotherapy.
Although early recognition of cancer may not benefit these
patients since they often have widely disseminated disease,
some cases of improvement under treatment have been
described.14 Second, the diagnosis allows establishing a prog-
nosis: 90% of patients will die within 1 month, although it will
depend on the underlying malignancy.5 Finally, timely diag-
nosis of systemic malignancy allows not starting or discontinu-
ing plasma exchanges since this treatment is ineffective and can
even be counterproductive. Indeed, some authors have hypoth-
esized that plasma exchange might promote microthrombi
formation, thereby worsening a chronic compensated state.21
CONCLUSIONS
In summary, disseminated malignancy, especially gastric
Medicine  Volume 93, Number 24, November 2014cancer, and PTTM should be suspected in the presence of TMA
presenting with atypical characteristics of TTP and/or alteration
in coagulation tests, especially with lung involvement. These
# 2014 Lippincott Williams & Wilkins
patients usually need ICU admission and their outcome is
rapidly fatal, so they are a medical challenge. Prompt diagnosis
is important in order to establish a correct treatment and
prognosis, avoiding ineffective therapies.
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